To review the U.S. Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience database for reports describing serious adverse events and adverse events reports describing use outside of the manufacturers' labeled instructions for the five FDA-approved minimally invasive endometrial ablation devices.
We queried the Manufacturer and User Facility Device Experience database for reports of device malfunction, patient injury, or death reported for each device from January 1, 2005 to December 31, 2011. We reviewed U.S. reports individually for annotations of patient injury or death and tabulated the reports by type of injury and device. We identified nine categories of serious injury (death, sepsis or bacteremia, intra-abdominal abscess, uterine rupture, thermal bowel injury, mechanical bowel injury, transmural uterine thermal injury, urologic injury, and lower genital tract or skin burns) and noted all reports citing device use outside of the manufacturers' labeled instructions. We also identified reports of hysterectomy or bowel resection attributable to an adverse event.
Serious adverse events, including bowel injury (n=128), sepsis or bacteremia (n=47), intra-abdominal abscess (n=18), urologic injury (n=2), and uterine rupture (n=1) were reported. Death was also reported (n=4). Eight percent (66 of 829) of serious adverse events reports cited use outside of the manufacturers' labeled instructions, as did 7.3% (6 of 82) of reports citing need for hysterectomy and 8.7% (9 of 103) of reports of bowel resection.
The findings from the Manufacturer and User Facility Device Experience database highlight the potential risk of serious complications related to endometrial ablation and underscore the importance of training in correct device use and familiarity with the manufacturer's labeled instructions.
The U.S. Food and Drug Administration Manufacturer and User Facility Device Experience database provides valuable information regarding serious complications associated with minimally invasive endometrial ablation devices.
From the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and the George Washington University School of Medicine, Washington, DC.
The authors thank Nancy Pressly for providing search results from the MAUDE database, and Dr. John Larsen for valuable editorial input.
The views expressed in this article reflect the opinions of the authors only and not the official policy of the Department of Health and Human Services.
Corresponding author: Jill Brown, MD, MPH, National Institutes of Health, NIAID/DMID/STDB, 6610 Rockledge Drive, Room 3106, Bethesda, MD 20892; e-mail: email@example.com.
Financial Disclosure The authors did not report any potential conflicts of interest.